Abstracts tagged "Gout and quality of life"

Abstract Number: 1994 • 2013 ACR/ARHP Annual Meeting
Performance Of Gout Impact Scale Of The Gout Assessment Questionnaire In a Longitudinal Observational Study Of Patients With Gout
Puja Khanna¹, Cleopatra Aquino-Beaton², Jasvinder A. Singh³, Erin Duffy⁴, David Elashoff⁵ and Dinesh Khanna⁶, ¹Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI, ²Rheumatology, VA Greater Los Angeles Healthcare System, Los Angeles, CA, ³Department of Medicine, University of Alabama, Tuscaloosa, AL, ⁴Medicine, University of California Los Angeles, Los Angeles, CA, ⁵Medicine- Statistic Core, UCLA Department of Medicine Statistics Core, Los Angeles, CA, ⁶University of Michigan Health System, Ann Arbor, MI
Background/Purpose: Gout Assessment Questionnaire (GAQ2.0) is a validated disease-specific measure used to evaluate patient reported outcomes in gout studies. The objective was to evaluate the…
Abstract Number: 142 • 2012 ACR/ARHP Annual Meeting
Efficacy of Canakinumab Versus Triamcinolone Acetonide According to Multiple Gouty Arthritis-Related Health Outcomes Measures
Ari Gnanasakthy¹, Andrew Sarkin², Rachel Lale², Kyle Choi² and Jan D. Hirsch³, ¹Novartis Pharmaceuticals Corporation, East Hanover, NJ, ²Health Services Research Center, University of California, San Diego, CA, ³Skaggs School of Pharmacy & Pharmaceutical Sciences, University of California, San Diego, CA
Background/Purpose: Canakinumab (CAN), a selective, fully human, anti-IL-1β monoclonal antibody, may be a potential therapeutic option for treating acute gout attacks and delaying new attacks…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].